CN104230777B - A kind of synthetic method of oxiracetam - Google Patents
A kind of synthetic method of oxiracetam Download PDFInfo
- Publication number
- CN104230777B CN104230777B CN201310243165.7A CN201310243165A CN104230777B CN 104230777 B CN104230777 B CN 104230777B CN 201310243165 A CN201310243165 A CN 201310243165A CN 104230777 B CN104230777 B CN 104230777B
- Authority
- CN
- China
- Prior art keywords
- intermediate compound
- oxiracetam
- alcohol
- amino
- hydroxybutyrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
The synthetic method of a kind of (S) oxiracetam, comprises the steps: that (1), with S 4 amino 3 hydroxybutyric acid as initiation material, carries out esterification with alcohol, obtains intermediate compound I；(2) intermediate compound I and halogenated acetic acids ester are carried out condensation reaction, it is thus achieved that intermediate II；(3) intermediate II is carried out ring closure reaction and obtain intermediate III；(4) intermediate III is carried out ammonolysis reaction, obtain target product (S) oxiracetam.Oxiracetam synthetic route of the present invention at least can obtain (S) oxiracetam product of more than 20% more satisfactory yield, opens a new oxiracetam synthetic route.
Description
Technical field
The present invention relates to the synthetic method of a kind of oxiracetam, particularly relate to the synthetic method of one (S)-oxiracetam.
Background technology
Oxiracetam is the nootropics synthesized first in 1974 than Qie Mu company by Italy SmithKline, is by two kinds of isomeries
The raceme that body (S)-oxiracetam ((S)-oxiracetam) and (R)-oxiracetam ((R)-oxiracetam) form.(S)-
Oxiracetam is a single enantiomer of oxiracetam, and chemistry is entitled: (S)-4-hydroxyl-2 oxo-1-pyrrolidine ethanamide.
Nootropics oxiracetam is hydroxy-amino-butyric acid (GABOB) derivant of a kind of synthesis, and it is that a kind of can promotion learns, and strengthens note
Recall power, the medicine for central nervous system of protection damaged nerve cell.
At present, the method for synthesis (the S)-oxiracetam of document report has four kinds:
United States Patent (USP) US4173569 has addressed the synthetic method of a kind of (S)-oxiracetam: (S)-4-amino-3-hydroxyl fourth
Acid is initiation material, protects hydroxyl through sillylation reagent, and the product after cyclization reacts with halogenated acetic acids ethyl ester, product
Through Deprotection, ammonolysis, finally obtain target compound.This kind of preparation method is not suitable for industrial-scale production, because it
Have disadvantages that, reactions steps can be increased as used protection group that hydroxyl is carried out protection, waste raw material, the longest, increase into
This, make total recovery reduce.It addition, in this course of reaction, need intermediate is carried out column chromatography purification, just can carry out next step
Reaction.These shortcomings are all the most disadvantageous for industrial-scale production.
Document: Tetrahedron:Asymmetry 1992,3 (11) reports a kind of method synthesizing this compound；With
Malic acid and glycine methyl ester are initiation material, and chloroacetic chloride protection hydroxyl, chosen property is reduced, removed hydroxyl, Deprotection, ammonia
Solve, obtain target compound.In this approach, need to carry out a selective reduction and cause the multiple by-product of generation, and
Each intermediate is required for column chromatography purification, just can carry out next step reaction.Such technique can not meet industrialization equally
The requirement of scale.
Technology disclosed in patent W02005/115978, wherein (S)-4-chloro-3-hydroxyl ethyl n-butyrate. reacts with Aminoacetamide
Obtain target compound, or react with glycine ethyl ester, then obtain target compound through ammonolysis.Wherein (S)-4-chloro-3-hydroxyl
Base butyrate and sweet amine amide react that to obtain final products oxiracetam be to control by disposably adding alkali in the basic conditions
The alkalescence of reactant liquor, but owing to oxiracetam is more easily damaged in strong base solution, so directly affects the pure of oxiracetam
Degree and yield；Additionally using silica gel column chromatography method in purification final products oxiracetam, the eluent of use is organic mixed
Bonding solvent, quantity of solvent is big, is not easily recycled, and cost is high, and silica gel column chromatography method is also not suitable for industrial amplification production.
Chinese patent CN10575309A reports one to be carried out with glycine and S-4-halogen-3-hydroxybutyrate ester for raw material
Condensation, then carry out being esterified the synthetic route of ammonolysis, but the method uses the mode dripping highly basic under hot conditions to carry out equally
Condensation, can cause being condensed yield relatively low with multiple side reactions such as S-4-halogen-3-hydroxybutyrate ester hydrolysis while condensation,
By-product is more, obtains end-product S-oxiracetam and cannot separate out by direct crystallization under this purity, needs ion exchange resin
Chromatography remove impurity, cost is high, and purity is low, it is difficult to industrialization.
Summary of the invention
It is an object of the invention to provide the synthetic method of a kind of oxiracetam, the inventive method is simple to operate, purity is high,
Yield is high.
The object of the invention is achieved through the following technical solutions:
The synthetic method of a kind of (S)-oxiracetam, comprises the steps:
(1) with S-4-amino-3-hydroxybutyrate as initiation material, carry out esterification with alcohol, obtain (S)-intermediate compound I；
(2) (S)-intermediate compound I and halogenated acetic acids ester are carried out condensation reaction, it is thus achieved that (S)-intermediate II；
(3) (S)-intermediate II is carried out ring closure reaction and obtain (S)-intermediate III；
(4) (S)-intermediate III is carried out ammonolysis reaction, obtain target product (S)-oxiracetam.Reaction expression is as follows:
Inventor studies through long-term experiment, has attempted a lot of new synthesis route and has all been difficult to obtain (S)-oxiracetam,
Eventually by above synthetic route, by above each response type and the cooperation of sequencing thus obtain more than 20% more satisfactory yield
(S)-oxiracetam product, open a new oxiracetam synthetic route.
So that impurity is more easily separated, operating procedure simple, thus obtain high-purity product, the work of promotion pharmaceutical production
Industry, the most also ensures that reaction yield, the halogenated acetic acids ester in above-mentioned steps (2) preferably employ bromoacetate, monoxone second
Ester, bromoacetic acid N-butyl, bromide isobutyl acetate, bromo-acetic acid tert-butyl or benzyl acetate bromide.
Improving reaction yield further to improve reactivity further, above-mentioned (1) is preferably a step:
S-4-amino-3-hydroxybutyrate is added in alcohol, also under conditions of instilling acylating agent or catalyst, be esterified
Reaction obtains (S)-intermediate compound I；The optional methanol of described alcohol, ethanol, normal propyl alcohol, isopropanol, n-butyl alcohol, the tert-butyl alcohol, Hexalin or
Cyclopentanol, it is preferred to use methanol, ethanol, normal propyl alcohol or cyclopentanol；Described acylating agent be concentrated hydrochloric acid, concentrated sulphuric acid, thionyl chloride, three
Chlorethoxyfos, phosphorus pentachloride or oxalyl chloride；Described catalyst is concentrated sulphuric acid, Loprazolam, p-methyl benzenesulfonic acid or trifluoroacetic acid.
(S)-intermediate compound I formula is as follows:
R1 is methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, the tert-butyl group, isobutyl group, cyclopenta or cyclohexyl etc..
In order to further improve reactivity, improve reaction yield, above-mentioned acylating agent or catalyst and S-4-amino-3-
The mol ratio of hydroxybutyric acid is: S-4-amino-3-hydroxybutyrate: acylating agent or catalyst=1: 1～2.5.
More specifically, above-mentioned (1) step is:
First the above-mentioned alcohol of S-4-amino-3-hydroxybutyrate and 5～20 times of weight is mixed, be subsequently adding above-mentioned acylating agent or
Catalyst reacts 1～5 hour at 0～60 DEG C, and S-4-amino-3-hydroxybutyrate is 1 with acylating agent or catalyst molar ratio:
1.5～1.65；The acquisition alcoholic solution containing (S)-intermediate compound I, then collection (S) from the alcoholic solution containing (S)-intermediate compound I-
Intermediate compound I.
Above-mentioned S-4-amino-3-hydroxybutyrate, alcohol and acylating reagent are commercially available prod.
Above-mentioned (2) step, specifically, will obtain (S)-intermediate compound I from step (1), in a solvent with halo second
Acid esters reacts 5～10 hours in the presence of base catalyst, and reaction temperature is 0～60 DEG C, then collects acquisition (S)-intermediate II；
Described solvent is without particular/special requirement, one or more groups in prioritizing selection methanol, ethanol, isopropanol, oxolane, DMF, DMSO
Close；Described base catalyst is preferably pyridine, triethylamine, lutidines, potassium carbonate or sodium bicarbonate.
In order to further improve reaction purity and yield, (S)-intermediate compound I with the mol ratio of halogenated acetic acids ester is: 1: 1
～3, (S)-intermediate compound I with the mol ratio of described base catalyst is: 1: 2～3.
Most specifically say that above-mentioned (2) step will obtain (S)-intermediate compound I from step (1), at S-4-amino-3-hydroxyl
The solvent of the 10-15 times of weight of base butanoic acid reacts 5～10 hours with halogenated acetic acids ester in the presence of base catalyst, reaction temperature
It is 0～60 DEG C, then collects acquisition (S)-intermediate II；Described solvent is without particular/special requirement, prioritizing selection methanol, ethanol, isopropyl
One or more combinations in alcohol, oxolane, DMF, DMSO；Described base catalyst is preferably pyridine, triethylamine, dimethyl
Pyridine, potassium carbonate or sodium bicarbonate；(S)-intermediate compound I with the mol ratio of halogenated acetic acids ester is: 1: 1～3, (S)-intermediate compound I with
The mol ratio of described base catalyst is: 1: 2～3.
(S)-intermediate II formula is as follows:
R1 is methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, the tert-butyl group, isobutyl group, cyclopenta or cyclohexyl etc.；
R2 is ethyl, n-pro-pyl, isopropyl, normal-butyl, the tert-butyl group, isobutyl group, benzyl or cyclopenta etc..
Above-mentioned steps (3), specifically, (S)-intermediate II that step (2) is obtained, in a solvent 50～130 DEG C of bars
Carrying out ring closure reaction under part, the time is 3～8 hours, it is thus achieved that containing the solution of (S)-intermediate III, then from containing (S)-
The solution of mesosome III is collected and obtains (S)-intermediate III；Described solvent may select: ethanol, the tert-butyl alcohol, toluene, diformazan
Benzene, water, ethyl acetate, butyl acetate or ethyl n-butyrate., it is preferred to use ethanol, toluene or dimethylbenzene.
(S)-intermediate III formula is as follows:
R2 is ethyl, n-pro-pyl, isopropyl, normal-butyl, the tert-butyl group, isobutyl group, benzyl or methoxybenzyl etc..
In order to further improve reaction purity and yield, (S)-intermediate II is 1: 10～30 with the mol ratio of solvent.
Above-mentioned steps (4), specifically, (S)-intermediate III step (3) obtained, with dense ammonia at 20～30 DEG C
Water reacts 4～16 hours, then collects target product (S)-oxiracetam from product.
Overall yield of reaction is improved, above-mentioned (S)-intermediate III: the mol ratio of ammonia in order to improve reactivity further
For (S)-intermediate III: ammonia=1: 12～15, in terms of the ammonia in ammonia methanol solution；Described strong aqua ammonia is known in the art
, the concentrations by weight of its solution is 25～about 28%.
The method collecting target product (S)-oxiracetam from the product of above-mentioned steps (4), preferably by following step
Rapid: product is dissolved in the water, heating for dissolving, activated carbon decolorizing, it is filtered to remove activated carbon, concentrating under reduced pressure removes water, when surplus
Remaining water is for adding products weight 2～stopping when 3 times concentrating, 0～5 DEG C of sub-cooled crystallization, it is thus achieved that product (S)-Aura west
Smooth.
The synthetic method of a kind of DL body oxiracetam, it is characterised in that comprise the steps:
(1) with 4-amino-3-hydroxybutyrate as initiation material, carry out esterification with alcohol, obtain intermediate compound I；
(2) intermediate compound I and halogenated acetic acids ester are carried out condensation reaction, it is thus achieved that intermediate II；
(3) intermediate II is carried out ring closure reaction and obtain intermediate III；
(4) intermediate III is carried out ammonolysis reaction, obtain target product oxiracetam.
Inventor has attempted a lot of new synthesis route and has all been difficult to obtain oxiracetam, final by above synthetic route, passes through
Coordinating thus obtaining the oxiracetam product of more than 20% more satisfactory yield of the most each response type and sequencing, opens
Article one, new oxiracetam synthetic route.
Preferably, the halogenated acetic acids ester in above-mentioned steps (2) preferably employs bromoacetate, ethyl chloroacetate, bromoacetic acid
N-butyl, bromide isobutyl acetate, bromo-acetic acid tert-butyl or benzyl acetate bromide.
Further preferably saying, above-mentioned (1) step is: first mixed by the alcohol of 4-amino-3-hydroxybutyrate and 5～20 times of weight
Close, be subsequently adding acylating agent or catalyst and react 1～5 hour at 0～60 DEG C, 4-amino-3-hydroxybutyrate and acylating agent or
Catalyst molar ratio is 1: 1.5～1.65；Obtain the alcoholic solution containing intermediate compound I, then from the alcoholic solution containing intermediate compound I
Collect intermediate compound I；Described alcohol is methanol, ethanol, normal propyl alcohol, isopropanol, n-butyl alcohol, the tert-butyl alcohol, Hexalin or cyclopentanol；Described
Acylating agent is concentrated hydrochloric acid, concentrated sulphuric acid, thionyl chloride, phosphorus oxychloride, phosphorus pentachloride or oxalyl chloride；Described catalyst be concentrated sulphuric acid,
Loprazolam, p-methyl benzenesulfonic acid or trifluoroacetic acid.
Specifically, above-mentioned (2) step: be the intermediate compound I that will obtain from step (1), at 4-amino-3-hydroxybutyrate
Reacting in the presence of base catalyst 5～10 hours with halogenated acetic acids ester in the solvent of 10-15 times of weight, reaction temperature is 0～60
DEG C, then collect and obtain intermediate II；Described solvent selects in methanol, ethanol, isopropanol, oxolane, DMF, DMSO
Plant or multiple combination；Described base catalyst is preferably pyridine, triethylamine, lutidines, potassium carbonate or sodium bicarbonate；Middle
Body I with the mol ratio of halogenated acetic acids ester is: 1: 1～3, and intermediate compound I with the mol ratio of described base catalyst is: 1: 2～3.
There is advantages that
Oxiracetam synthetic route of the present invention is a synthetic route being suitable to industrialized production, be especially advantageous for product point
From purification, synthetic route of the present invention at least can obtain (S)-oxiracetam or the DL body Aura west of more than 20% more satisfactory yield
Smooth product, opens a new oxiracetam synthetic route.Meanwhile, synthetic route of the present invention is by further optimal control bar
Final (S)-oxiracetam that part obtains or the purity of DL body oxiracetam product and optical purity all up to more than 99.9%,
Total recovery reaches 48.2%.Meanwhile, use the synthetic method of the present invention (S)-oxiracetam or DL body oxiracetam with existing
Technology compare, raw material is cheap and easy to get, and purification is without column chromatography, low cost, easy and simple to handle, better quality.The present invention opens
Article one, new oxiracetam synthetic route.
Detailed description of the invention
Below by embodiment, the present invention is specifically described, it is necessary to it is pointed out here that, following example are only used
In the present invention is further detailed, it is impossible to be interpreted as limiting the scope of the invention, being skilled in technique of this field
The present invention can be made some nonessential improvement and adjustment according to foregoing invention content by personnel.
Embodiment 1
A kind of synthetic method of (S)-oxiracetam, it carries out as follows,
(1) preparation of (S)-intermediate compound I:
Take raw material S-4-amino-3-hydroxybutyrate 50g, add in a single neck bottle, add methanol 50ml, stirring, ice-water bath
Cooling, is slowly dropped into concentrated hydrochloric acid 150ml, keeps temperature less than 40 DEG C, and solid first has a course of dissolution, separates out the most again,
Drip solid when making a concentrated effort to finish to dissolve again, eventually form a faint yellow supernatant liquid.Continuing stirring 3 hours, raw material base is shown in by some plate
This reaction is complete, stopped reaction, directly concentrates removing solvent and obtains pale yellow oil, and curing at low temperatures obtains (S)-intermediate compound I.
Detecting through nuclear-magnetism, (S)-intermediate compound I is: 1H-NMR (300MHz, D2O): δ 2.76-2.67 (AB system, m, 2H), 3.31-
3.23 (AB system, m, 2H), 3.75 (s, 3H), 4.40 (m, 1H), 4.70 (bs, 3H) .13C-NMR (50MHz, D2O): δ
43.7 (C-2), 48.4 (C-4), 57.0 (OCH), 68.9 (C-3), 177.5 (C-I). (S)-intermediate compound I is:R1 is methyl.
(2) preparation of (S)-intermediate II
(S)-intermediate compound I that step (1) obtains is dissolved in the methanol of 500ml, is cooled to outer temperature 0 DEG C, add carbonic acid
Potassium 173g (3eq), has a large amount of solid to generate, and stirs five minutes, starts to drip bromoacetate 90ml (2eq), and dropping process has
Exothermic phenomenon, drips complete follow-up continuous stirring 2 hours, and some plate is shown in that raw material reaction is complete, and stopped reaction adds EA (ethyl acetate)
500ml, water 300ml, solid is completely dissolved, and by saturated for water layer solid sodium chloride, separates organic layer, and water layer EA 200ml extracts
Taking twice, merge organic layer, the hydrochloric acid 200ml of organic layer 2M washes three times, merges hydrochloric acid aqueous phase, and organic facies discards, and aqueous phase continues
Continuing and regulate pH to 8 with sodium bicarbonate, solid sodium chloride is saturated, and EA 300ml extracts three times, merges organic facies, and anhydrous magnesium sulfate is done
Dry, concentrate removing solvent and obtain pale yellow oil, curing at low temperatures obtains (S)-intermediate II.Detect through nuclear-magnetism, (S)-in
Mesosome II:1H-NMR (300MHz, D2O): δ 1.3 (t, 3H), 2.28-2.53 (m, 2H), 2.58-2.83 (m, 2H) 3.51 (s,
2H), 3.67 (s, 3H), 4.09-4.12 (m, 3H). (S)-intermediate II is:
R1 is methyl, and R2 is ethyl.
(3) preparation of (S)-intermediate III
(S)-intermediate II 500ml ethanol step (2) obtained dissolves, and is warming up to 75 DEG C, refluxes 8 hours, obtain
One red tan solution, some plate is shown in that raw material reaction is complete.Stopped reaction, concentrates and removes ethanol, adds EA (ethyl acetate) and dissolves, mistake
Filter and desalt, activated carbon decolorizing, concentrate remove yellow oil obtains (S)-intermediate III.Detect through nuclear-magnetism, (S)-middle
Body III is: 1H-NMR (300MHz, CDCl3) δ 1.280 (t, 3H), 2.38 (dd, 1H), 2.69 (dd, 1H), 3.34 (dd, 1H),
3.77 (dd, 1H), 3.93 (d, 1H), 4.18 (d, 1H), 4.19 (q, 2H), 4.30 (bs, 1H), 4.50 (m, 1H). (S)-middle
Body III:
R2 is ethyl.
(4) preparation of (S)-oxiracetam
(S)-intermediate III step (3) obtained adds strong aqua ammonia 200ml, is stirred at room temperature 18 hours, and raw material is shown in by some plate
Completely, stopped reaction, concentration is removed water and ammonia, is obtained yellow oil, adds acetone solution grease, adds a small amount of in reaction
Crystal seed stirs, and separates out solid, a small amount of acetone rinsing bottle wall, and-10 DEG C crystallize 5 hours, are filtrated to get off-white color crude product 36g.Purity
99.3%, isomer proportion 0.2%.By this dissolving crude product in the water of 100ml, heating makes it dissolve, and activated carbon decolorizing half is little
Time, it is filtered to remove activated carbon, crystallisation by cooling, 5 DEG C stand overnight, and filter to obtain white solid 32g, purity 99.9%, isomery next day
Body ratio 0.1%, yield is 48.2%, detects through nuclear-magnetism, levo-oxiracetam: 1H-NMR (300MHz, DMSO-d6) δ 2.10
(d, 1H), 2.57 (dd, 1H), 3.69 (d, 1H), 3.88 (d, 1H), 4.10 (d, 1H), 4.31 (m, 1H), 5.25 (s, 1H),
7.13 (s, 1H), 7.33 (s, 1H). optical value :-37.3.
(S)-oxiracetam is that structural formula is as follows:
Embodiment 2
1, the synthetic method of a kind of (S)-oxiracetam, as follows:
(1) by S-4-amino-3-hydroxybutyrate and the ethanol accounting for its 18 times of weight, stirring, react esterification 5 at 60 DEG C
About hour, raw material fundamental reaction is complete, stopped reaction, directly concentrates and removes solvent, and curing at low temperatures obtains (S)-intermediate
I；Simultaneously above solvent additionally uses methanol, normal propyl alcohol, isopropanol, n-butyl alcohol, the tert-butyl alcohol, Hexalin or cyclopentanol etc. and prepares
(S)-intermediate compound I, after detect through nuclear-magnetism, obtained (S)-intermediate compound I is: 1H-NMR (300MHz, D2O): δ 1.30 (m,
3H), 2.76-2.67 (AB system, m, 2H), 3.31-3.23 (AB system, m, 2H), 4.12 (m, 2H), 4.40 (m,
1H), 4.70 (bs, 3H)..
(2) (the S)-intermediate compound I that will obtain from step (1), at the ethanol of 15 times of weight of S-4-amino-3-hydroxybutyrate
In, stirring cooling, dropping 60 DEG C of condensation reactions of bromoacetic acid N-butyl 10 hours, described (S)-intermediate compound I and halogenated acetic acids ester
Mol ratio is 1: 1.5, then collects acquisition (S)-intermediate II, and above solvent additionally uses methanol, isopropanol, tetrahydrochysene furan simultaneously
Mutter, DMF or DMSO etc. prepares (S)-intermediate II, after detect through nuclear-magnetism, obtained (S)-intermediate II is: 1H-NMR
(300MHz, D2O): δ 0.96 (t, 3H), 1.30-1.33 (m, 5H), 1.57 (m, 2H), 2.28-2.53 (m, 2H), 2.58-2.83
(m, 2H) 3.51 (s, 2H), 4.08-4.12 (m, 5H)..
(3) (S)-intermediate II step (2) obtained, is dissolved in ethyl acetate, described (S)-intermediate II and second
The mol ratio of acetoacetic ester is 1: 12, is warming up at 85 DEG C carry out ring closure reaction 6.5 hours, it is thus achieved that containing (S)-intermediate III
Solution, then collects from the solution containing (S)-intermediate III and obtains (S)-intermediate III, and described solvent additionally uses
For ethanol, the tert-butyl alcohol, toluene, dimethylbenzene, water, butyl acetate or ethyl n-butyrate., after detect through nuclear-magnetism, obtained (S)-in
Mesosome III is: 1H-NMR (300MHz, CDCl3) δ 0.96 (t, 3H) 1.33 (m, 2H), 1.57 (m, 2H) 2.38 (dd, 1H),
2.69 (dd, 1H), 3.34 (dd, 1H), 3.77 (dd, 1H), 3.93 (d, 1H), 4.18 (d, 1H), 4.19 (q, 2H), 4.30 (bs,
1H), 4.50 (m, 1H)..
(4) (S)-intermediate III of step (3) being obtained adds in strong aqua ammonia, is stirred at room temperature that to carry out ammonolysis reaction 15 little
Time, described (S)-intermediate III: the mol ratio of ammonia is (S)-intermediate III: ammonia=1:13, with the ammonia in ammonia methanol solution
Meter；Reaction concentrates remove water and ammonia completely, uses acetone purification, crystallization to obtain product (S)-oxiracetam crude product.Crude product is molten
In Xie Yushui, heating for dissolving, activated carbon decolorizing, it is filtered to remove activated carbon, concentrating under reduced pressure removes water, when surplus water is for adding product
Weight 2～stop when 3 times concentrating, 0～5 DEG C of sub-cooled crystallization, it is thus achieved that product (S)-oxiracetam.HPLC measures its purity
80.4%, calculate yield is 20%, through nuclear-magnetism detect, gained levo-oxiracetam is: 1H-NMR (300MHz, DMSO-d6)
52.10 (d, 1H), 2.57 (dd, 1H), 3.69 (d, 1H), 3.88 (d, 1H), 4.10 (d, 1H), 4.31 (m, 1H), 5.25 (s,
1H), 7.13 (s, 1H), 7.33 (s, 1H). optical value :-37.2.
Embodiment 3-12: the embodiment optimized further for the present invention relative to embodiment 2,
Step and parameter by table 1 below are carried out, other same as in Example 1.
Table 1
Detecting through nuclear-magnetism, intermediate prepared by embodiment 3-12 is as shown in table 2 with levo-oxiracetam:
The levo-oxiracetam prepared by above example 3-12 measures its purity at 99.5-99.9% through HPLC, calculates
Yield is at 35-45%.
Embodiment 13
1, the synthetic method of a kind of DL body oxiracetam, as follows:
(1) by 4-amino-3-hydroxybutyrate and the ethanol accounting for its 18 times of weight, stirring, little 60 DEG C of reaction esterifications 5
Time about, raw material fundamental reaction is complete, stopped reaction, directly concentrates and removes solvent, and curing at low temperatures obtains intermediate compound I；Simultaneously
Above solvent additionally uses methanol, normal propyl alcohol, isopropanol, n-butyl alcohol, the tert-butyl alcohol, Hexalin or cyclopentanol etc. and prepares intermediate
I, after detect through nuclear-magnetism, obtained intermediate compound I is: 1H-NMR (300MHz, D2O): δ 1.28 (m, 3H), 2.75-2.66
(AB system, m, 2H), 3.30-3.22 (AB system, m, 2H), 4.09 (m, 2H), 4.39 (m, 1H), 4.72 (bs,
3H).。
(2) intermediate compound I that will obtain from step (1), in the ethanol of 15 times of weight of 4-amino-3-hydroxybutyrate, stirs
Mixing cooling, dropping 60 DEG C of condensation reactions of bromoacetic acid N-butyl 10 hours, described intermediate compound I is 1 with the mol ratio of halogenated acetic acids ester:
1.5, then collect and obtain intermediate II, above solvent additionally uses methanol, isopropanol, oxolane, DMF or DMSO etc. simultaneously
Prepare intermediate II, after detect through nuclear-magnetism, obtained intermediate II is: 1H-NMR (300MHz, D2O): δ 0.95 (t,
3H), 1.31-1.34 (m, 5H), 1.55 (m, 2H), 2.29-2.54 (m, 2H), 2.56-2.81 (m, 2H) 3.50 (s, 2H),
(4.05-4.10 m, 5H)..
(3) intermediate II step (2) obtained, is dissolved in ethyl acetate, described intermediate II and ethyl acetate
Mol ratio is 1: 12, is warming up at 85 DEG C carry out ring closure reaction 6.5 hours, it is thus achieved that containing the solution of intermediate III, then from containing
Have in the solution of intermediate III collect obtain intermediate III, described solvent additionally use into ethanol, the tert-butyl alcohol, toluene, two
Toluene, water, butyl acetate or ethyl n-butyrate., after detect through nuclear-magnetism, obtained intermediate III is: 1H-NMR (300MHz,
CDC13) δ 0.94 (t, 3H) 1.32 (m, 2H), 1.55 (m, 2H) 2.37 (dd, 1H), 2.68 (dd, 1H), 3.33 (dd, 1H),
3.77 (dd, 1H), 3.92 (d, 1H), 4.16 (d, 1H), 4.18 (q, 2H), 4.31 (bs, 1H), 4.50 (m, 1H)..
(4) intermediate III step (3) obtained adds in strong aqua ammonia, is stirred at room temperature and carries out ammonolysis reaction 15 hours, institute
State intermediate III: the mol ratio of ammonia is intermediate III: ammonia=1: 13, in terms of the ammonia in ammonia methanol solution；React the denseest
Contracting is removed and ammonia, uses acetone purification, crystallization to obtain product (S)-oxiracetam crude product.By dissolving crude product in water, heating
Dissolving, activated carbon decolorizing, be filtered to remove activated carbon, concentrating under reduced pressure removes water, when surplus water is for addition products weight 2～3 times
Stop concentrating, 0～5 DEG C of sub-cooled crystallization, it is thus achieved that product DL body oxiracetam.It is 82.1% that HPLC measures its purity, calculates
Yield is 19.5%, detect through nuclear-magnetism, gained DL body oxiracetam is: 1H-NMR (300MHz, DMSO-d6) δ 2.05 (d,
1H), 2.43 (dd, 1H), 3.57 (d, 1H), 3.78 (d, 1H), 4.10 (d, 1H), 4.35 (m, 1H), 5.31 (s, 1H), 7.23
(s, 1H), 7.43 (s, 1H).
Claims (17)
1. the synthetic method of (S)-oxiracetam, it is characterised in that reaction expression is as follows:
Wherein R1For methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, the tert-butyl group, isobutyl group, cyclopenta or cyclohexyl；Described R2
For ethyl, n-pro-pyl, isopropyl, normal-butyl, the tert-butyl group, isobutyl group, benzyl or cyclopenta；
Comprise the steps:
(1) with S-4-amino-3-hydroxybutyrate as initiation material, carry out esterification with alcohol, obtain (S)-intermediate compound I；
(2) (S)-intermediate compound I and halogenated acetic acids ester are carried out condensation reaction, it is thus achieved that (S)-intermediate II；
(3) (S)-intermediate II is carried out ring closure reaction and obtain (S)-intermediate III；
(4) (S)-intermediate III is carried out ammonolysis reaction, obtain target product (S)-oxiracetam；
Described step (2) will obtain (S)-intermediate compound I from step (1), in a solvent with halogenated acetic acids ester at base catalyst
In the presence of react 5～10 hours, reaction temperature is 0～60 DEG C, then collects acquisition (S)-intermediate II；Described solvent may select
One or more combinations in methanol, ethanol, isopropanol, oxolane, DMF, DMSO；Described base catalyst be pyridine, three
Ethamine, lutidines, potassium carbonate or sodium bicarbonate；Described (S)-intermediate compound I with the mol ratio of halogenated acetic acids ester is: 1: 1～
3, (S)-intermediate compound I with the mol ratio of described base catalyst is: 1: 2～3；
Step (2) is obtained (S)-intermediate II by described step (3), carries out cyclization under the conditions of 50～130 DEG C in a solvent
Reaction, the time is 3～8 hours, it is thus achieved that containing the solution of (S)-intermediate III, then from the solution containing (S)-intermediate III
Middle collection obtains (S)-intermediate III；Described solvent may select: ethanol, the tert-butyl alcohol, toluene, dimethylbenzene, water, ethyl acetate,
Butyl acetate or ethyl n-butyrate..
2. the synthetic method of (S)-oxiracetam as claimed in claim 1, it is characterised in that: the halo second in described step (2)
Acid esters uses bromoacetate, ethyl chloroacetate, bromoacetic acid N-butyl, bromide isobutyl acetate, bromo-acetic acid tert-butyl or bromoacetic acid
Benzyl ester.
3. the synthetic method of (S)-oxiracetam as claimed in claim 1 or 2, it is characterised in that described (1) step is:
S-4-amino-3-hydroxybutyrate is added in alcohol, under conditions of instilling acylating agent or catalyst, carry out esterification and obtain
To (S)-intermediate compound I；Described alcohol is methanol, ethanol, normal propyl alcohol, isopropanol, n-butyl alcohol, the tert-butyl alcohol, Hexalin or cyclopentanol；Institute
Stating acylating agent is concentrated hydrochloric acid, concentrated sulphuric acid, thionyl chloride, phosphorus oxychloride, phosphorus pentachloride or oxalyl chloride；Described catalyst is dense sulfur
Acid, Loprazolam, p-methyl benzenesulfonic acid or trifluoroacetic acid.
4. the synthetic method of (S)-oxiracetam as claimed in claim 3, it is characterised in that: described acylating agent or catalyst and S-
The mol ratio of 4-amino-3-hydroxybutyrate is: S-4-amino-3-hydroxybutyrate: acylating agent or catalyst=1: 1～2.5.
5. the synthetic method of (S)-oxiracetam as claimed in claim 3, it is characterised in that described (1) step is:
First the alcohol of S-4-amino-3-hydroxybutyrate and 5～20 times of weight is mixed, be subsequently adding acylating agent or catalyst 0～
Reacting 1～5 hour at 60 DEG C, S-4-amino-3-hydroxybutyrate is 1: 1.5～1.65 with acylating agent or catalyst molar ratio；Obtain
Then (S)-intermediate compound I must be collected from the alcoholic solution containing (S)-intermediate compound I containing the alcoholic solution of (S)-intermediate compound I.
6. the synthetic method of (S)-oxiracetam as described in any one of claim 1,2 or 4, it is characterised in that described (1) step
For:
First the alcohol of S-4-amino-3-hydroxybutyrate and 5～20 times of weight is mixed, be subsequently adding acylating agent or catalyst 0～
Reacting 1～5 hour at 60 DEG C, S-4-amino-3-hydroxybutyrate is 1: 1.5～1.65 with acylating agent or catalyst molar ratio；Obtain
Then (S)-intermediate compound I must be collected from the alcoholic solution containing (S)-intermediate compound I containing the alcoholic solution of (S)-intermediate compound I.
7. the synthetic method of (S)-oxiracetam as described in any one of claim 1,2,4 or 5, it is characterised in that described (2) step
Rapid: (S)-intermediate compound I will to be obtained from step (1), in the solvent of the 10-15 times of weight of S-4-amino-3-hydroxybutyrate
Reacting in the presence of base catalyst 5～10 hours with halogenated acetic acids ester, reaction temperature is 0～60 DEG C, then collect acquisition (S)-
Intermediate II；Described solvent selects one or more combinations in methanol, ethanol, isopropanol, oxolane, DMF, DMSO；Institute
The base catalyst said is pyridine, triethylamine, lutidines, potassium carbonate or sodium bicarbonate；(S)-intermediate compound I and halogenated acetic acids ester
Mol ratio be: 1: 1～3, (S)-intermediate compound I with the mol ratio of described base catalyst is: 1: 2～3.
8. the synthetic method of (S)-oxiracetam as claimed in claim 3, it is characterised in that described (2) step: be by from step
(1) (the S)-intermediate compound I obtained, exists with halogenated acetic acids ester in the solvent of the 10-15 times of weight of S-4-amino-3-hydroxybutyrate
Reacting 5～10 hours in the presence of base catalyst, reaction temperature is 0～60 DEG C, then collects acquisition (S)-intermediate II；Described molten
Agent selects one or more combinations in methanol, ethanol, isopropanol, oxolane, DMF, DMSO；Described base catalyst is pyrrole
Pyridine, triethylamine, lutidines, potassium carbonate or sodium bicarbonate；(S)-intermediate compound I with the mol ratio of halogenated acetic acids ester is: 1: 1～
3, (S)-intermediate compound I with the mol ratio of described base catalyst is: 1: 2～3.
9. the synthetic method of (S)-oxiracetam as claimed in claim 6, it is characterised in that described (2) step: be by from step
(1) (the S)-intermediate compound I obtained, exists with halogenated acetic acids ester in the solvent of the 10-15 times of weight of S-4-amino-3-hydroxybutyrate
Reacting 5～10 hours in the presence of base catalyst, reaction temperature is 0～60 DEG C, then collects acquisition (S)-intermediate II；Described molten
Agent selects one or more combinations in methanol, ethanol, isopropanol, oxolane, DMF, DMSO；Described base catalyst is pyrrole
Pyridine, triethylamine, lutidines, potassium carbonate or sodium bicarbonate；(S)-intermediate compound I with the mol ratio of halogenated acetic acids ester is: 1: 1～
3, (S)-intermediate compound I with the mol ratio of described base catalyst is: 1: 2～3.
10. the synthetic method of (S)-oxiracetam as claimed in claim 7, it is characterised in that: described (S)-intermediate II is with molten
The mol ratio of agent is 1: 10～30.
11. as described in claim 8 or 9 synthetic method of (S)-oxiracetam, it is characterised in that: described (S)-intermediate II with
The mol ratio of solvent is 1: 10～30.
The synthetic method of 12. (S)-oxiracetams as claimed in claim 1, it is characterised in that described step (4): be by step
(3) (the S)-intermediate III obtained, reacts with strong aqua ammonia at 20～30 DEG C 4～16 hours, then collects from product
Target product (S)-oxiracetam；Described (S)-intermediate III: the mol ratio of ammonia is (S)-intermediate III: ammonia=1: 12～
15, in terms of the ammonia in ammonia methanol solution.
The synthetic method of 13. (S)-oxiracetams as claimed in claim 3, it is characterised in that described step (4): be by step
(3) (the S)-intermediate III obtained, reacts with strong aqua ammonia at 20～30 DEG C 4～16 hours, then collects from product
Target product (S)-oxiracetam；Described (S)-intermediate III: the mol ratio of ammonia is (S)-intermediate III: ammonia=1: 12～
15, in terms of the ammonia in ammonia methanol solution.
The synthetic method of 14. (S)-oxiracetams as claimed in claim 1, it is characterised in that mainly carry out as follows:
(1), first by the alcohol of S-4-amino-3-hydroxybutyrate and 5～20 times of weight mix, be subsequently adding acylating agent or catalyst exists
Reacting 1～5 hour at 0～60 DEG C, S-4-amino-3-hydroxybutyrate is 1: 1.5～1.65 with acylating agent or catalyst molar ratio,
Obtain the alcoholic solution containing (S)-intermediate compound I, from the alcoholic solution containing (S)-intermediate compound I, then collect (S)-intermediate compound I；Institute
Stating alcohol is methanol, ethanol, normal propyl alcohol, isopropanol, n-butyl alcohol, the tert-butyl alcohol, Hexalin or cyclopentanol, and described acylating agent is dense salt
Acid, concentrated sulphuric acid, thionyl chloride, phosphorus oxychloride, phosphorus pentachloride or oxalyl chloride, described catalyst be concentrated sulphuric acid, Loprazolam, to first
Benzenesulfonic acid or trifluoroacetic acid；
(2), (the S)-intermediate compound I that will obtain from step (1), at the solvent of the 10-15 times of weight of S-4-amino-3-hydroxybutyrate
In react in the presence of base catalyst 5～10 hours with halogenated acetic acids ester, reaction temperature is 0～60 DEG C, then collects acquisition
(S)-intermediate II；Described solvent selects one or more groups in methanol, ethanol, isopropanol, oxolane, DMF, DMSO
Closing, described base catalyst is pyridine, triethylamine, lutidines, potassium carbonate or sodium bicarbonate, and described halogenated acetic acids ester is
Bromoacetate, ethyl chloroacetate, bromoacetic acid N-butyl, bromide isobutyl acetate, bromo-acetic acid tert-butyl or benzyl acetate bromide；Described
(S)-intermediate compound I with the mol ratio of halogenated acetic acids ester is: 1: 1～3, and (S)-intermediate compound I with the mol ratio of described base catalyst is:
1: 2～3；
(3), by step (2) obtain (S)-intermediate II, carry out ring closure reaction under the conditions of 50～130 DEG C in a solvent, time
Between be 3～8 hours, it is thus achieved that containing the solution of (S)-intermediate III, then collect from the solution containing (S)-intermediate III
Obtain (S)-intermediate III；Described solvent be ethanol, the tert-butyl alcohol, toluene, dimethylbenzene, water, ethyl acetate, butyl acetate or
Ethyl n-butyrate., described (S)-intermediate II is 1: 10～30 with the mol ratio of solvent；
(4) (the S)-intermediate III, by step (3) obtained, reacts with strong aqua ammonia 4～16 hours at 20～30 DEG C, obtains anti-
Answer product (S)-oxiracetam crude product；Described (S)-intermediate III: the mol ratio of ammonia is (S)-intermediate III: ammonia=1: 12～
15, in terms of the ammonia in ammonia methanol solution；
(5), (4) step gained product is dissolved in the water, heating for dissolving, activated carbon decolorizing, it is filtered to remove activated carbon, subtracts
Pressure concentrates except water, stops concentrating when surplus water is for addition products weight 2～3 times, 0～5 DEG C of sub-cooled crystallization, it is thus achieved that produce
Thing (S)-oxiracetam.
The synthetic method of 15. 1 kinds of oxiracetams, it is characterised in that reaction expression is as follows:
Comprise the steps:
(1) with 4-amino-3-hydroxybutyrate as initiation material, carry out esterification with alcohol, obtain intermediate compound I；
(2) intermediate compound I and halogenated acetic acids ester are carried out condensation reaction, it is thus achieved that intermediate II；
(3) intermediate II is carried out ring closure reaction and obtain intermediate III；
(4) intermediate III is carried out ammonolysis reaction, obtain target product oxiracetam；
Alcohol in described step (1) is methanol, ethanol, normal propyl alcohol, isopropanol, n-butyl alcohol, the tert-butyl alcohol, Hexalin or cyclopentanol；
Described (2) step is the intermediate compound I that will obtain from step (1), in the 10-15 times of weight of 4-amino-3-hydroxybutyrate
Reacting in the presence of base catalyst 5～10 hours with halogenated acetic acids ester in solvent, reaction temperature is 0～60 DEG C, then collects and obtains
Obtain intermediate II；Described solvent selects one or more combinations in methanol, ethanol, isopropanol, oxolane, DMF, DMSO；
Described base catalyst is pyridine, triethylamine, lutidines, potassium carbonate or sodium bicarbonate；Intermediate compound I and halogenated acetic acids ester
Mol ratio is: 1: 1～3, and intermediate compound I with the mol ratio of described base catalyst is: 1: 2～3；Described halogenated acetic acids ester uses bromine second
Acetoacetic ester, ethyl chloroacetate, bromoacetic acid N-butyl, bromide isobutyl acetate, bromo-acetic acid tert-butyl or benzyl acetate bromide；Described step
(3) being intermediate II step (2) obtained, carry out ring closure reaction under the conditions of 50～130 DEG C in a solvent, the time is 3～8 little
Time, it is thus achieved that containing the solution of intermediate III, then collect from the solution containing intermediate III and obtain intermediate III；Described
Solvent may select: ethanol, the tert-butyl alcohol, toluene, dimethylbenzene, water, ethyl acetate, butyl acetate or ethyl n-butyrate..
The synthetic method of 16. oxiracetams as claimed in claim 15, it is characterised in that described (1) step is:
First the alcohol of 4-amino-3-hydroxybutyrate and 5～20 times of weight is mixed, be subsequently adding acylating agent or catalyst 0～60
Reacting 1～5 hour at DEG C, 4-amino-3-hydroxybutyrate is 1: 1.5～1.65 with acylating agent or catalyst molar ratio；Acquisition contains
There is the alcoholic solution of intermediate compound I, from the alcoholic solution containing intermediate compound I, then collect intermediate compound I；Described alcohol is methanol, ethanol, just
Propanol, isopropanol, n-butyl alcohol, the tert-butyl alcohol, Hexalin or cyclopentanol；Described acylating agent be concentrated hydrochloric acid, concentrated sulphuric acid, thionyl chloride,
Phosphorus oxychloride, phosphorus pentachloride or oxalyl chloride；Described catalyst is concentrated sulphuric acid, Loprazolam, p-methyl benzenesulfonic acid or trifluoroacetic acid.
17. as described in claim 15 or 16 synthetic method of oxiracetam, it is characterised in that described (2) step: be by from step
Suddenly the intermediate compound I that (1) obtains, urges at alkali with halogenated acetic acids ester in the solvent of the 10-15 times of weight of 4-amino-3-hydroxybutyrate
Reacting 5～10 hours in the presence of agent, reaction temperature is 0～60 DEG C, then collects and obtains intermediate II；Described solvent selects first
One or more combinations in alcohol, ethanol, isopropanol, oxolane, DMF, DMSO；Described base catalyst is pyridine, three second
Amine, lutidines, potassium carbonate or sodium bicarbonate；Intermediate compound I with the mol ratio of halogenated acetic acids ester is: 1: 1～3, intermediate compound I with
The mol ratio of described base catalyst is: 1: 2～3.
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610882486.5A CN106631963A (en) | 2013-06-19 | 2013-06-19 | Oxiracetam compounding method |
| CN201610881945.8A CN106478482A (en) | 2013-06-19 | 2013-06-19 | A kind of synthetic method of Oxiracetam |
| CN201610560643.0A CN105968024A (en) | 2013-06-19 | 2013-06-19 | Synthesis method of oxiracetam |
| CN201610560685.4A CN106146379B (en) | 2013-06-19 | 2013-06-19 | A kind of synthetic method of Oxiracetam |
| CN201310243165.7A CN104230777B (en) | 2013-06-19 | 2013-06-19 | A kind of synthetic method of oxiracetam |
| CN201610854647.XA CN106631960A (en) | 2013-06-19 | 2013-06-19 | Method for synthesizing oxiracetam |
| CN201610750215.4A CN106349142A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
| CN201610754462.1A CN106349143A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
| CN201610854853.0A CN106631961A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310243165.7A CN104230777B (en) | 2013-06-19 | 2013-06-19 | A kind of synthetic method of oxiracetam |
Related Child Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610854647.XA Division CN106631960A (en) | 2013-06-19 | 2013-06-19 | Method for synthesizing oxiracetam |
| CN201610882486.5A Division CN106631963A (en) | 2013-06-19 | 2013-06-19 | Oxiracetam compounding method |
| CN201610854853.0A Division CN106631961A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
| CN201610750215.4A Division CN106349142A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
| CN201610560685.4A Division CN106146379B (en) | 2013-06-19 | 2013-06-19 | A kind of synthetic method of Oxiracetam |
| CN201610881945.8A Division CN106478482A (en) | 2013-06-19 | 2013-06-19 | A kind of synthetic method of Oxiracetam |
| CN201610754462.1A Division CN106349143A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
| CN201610560643.0A Division CN105968024A (en) | 2013-06-19 | 2013-06-19 | Synthesis method of oxiracetam |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104230777A CN104230777A (en) | 2014-12-24 |
| CN104230777B true CN104230777B (en) | 2016-12-28 |
Family
ID=52219787
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310243165.7A Active CN104230777B (en) | 2013-06-19 | 2013-06-19 | A kind of synthetic method of oxiracetam |
| CN201610854647.XA Pending CN106631960A (en) | 2013-06-19 | 2013-06-19 | Method for synthesizing oxiracetam |
| CN201610881945.8A Pending CN106478482A (en) | 2013-06-19 | 2013-06-19 | A kind of synthetic method of Oxiracetam |
| CN201610754462.1A Pending CN106349143A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
| CN201610560685.4A Active CN106146379B (en) | 2013-06-19 | 2013-06-19 | A kind of synthetic method of Oxiracetam |
| CN201610882486.5A Pending CN106631963A (en) | 2013-06-19 | 2013-06-19 | Oxiracetam compounding method |
| CN201610854853.0A Pending CN106631961A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
| CN201610560643.0A Pending CN105968024A (en) | 2013-06-19 | 2013-06-19 | Synthesis method of oxiracetam |
| CN201610750215.4A Pending CN106349142A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610854647.XA Pending CN106631960A (en) | 2013-06-19 | 2013-06-19 | Method for synthesizing oxiracetam |
| CN201610881945.8A Pending CN106478482A (en) | 2013-06-19 | 2013-06-19 | A kind of synthetic method of Oxiracetam |
| CN201610754462.1A Pending CN106349143A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
| CN201610560685.4A Active CN106146379B (en) | 2013-06-19 | 2013-06-19 | A kind of synthetic method of Oxiracetam |
| CN201610882486.5A Pending CN106631963A (en) | 2013-06-19 | 2013-06-19 | Oxiracetam compounding method |
| CN201610854853.0A Pending CN106631961A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
| CN201610560643.0A Pending CN105968024A (en) | 2013-06-19 | 2013-06-19 | Synthesis method of oxiracetam |
| CN201610750215.4A Pending CN106349142A (en) | 2013-06-19 | 2013-06-19 | Synthetic method of oxiracetam |
Country Status (1)
| Country | Link |
|---|---|
| CN (9) | CN104230777B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107021902A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | A kind of levo-oxiracetam crystal formation I preparation method |
| CN107021907A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | Levo-oxiracetam crystal formation II preparation method |
| CN107021909A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | A kind of levo-oxiracetam crystal formation II preparation method |
| CN107021910A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | The method for preparing S-oxiracetam crystal formation II |
| CN107021908A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | The method for preparing levo-oxiracetam crystal formation II |
| CN107021913A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | A kind of method for preparing levo-oxiracetam crystal formation I |
| CN107021897A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | A kind of method for preparing levo-oxiracetam crystal formation II |
| CN107021896A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | A kind of levo-oxiracetam crystal formation II preparation method |
| CN107021899A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | A kind of method for preparing levo-oxiracetam crystal formation II |
| CN107021914A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | Levo-oxiracetam crystal formation II preparation method |
| CN107021905A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | The method for preparing levo-oxiracetam crystal formation II |
| CN107021900A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | A kind of (S)-Oxiracetam crystal form II preparation method |
| CN107021904A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | The method for preparing levo-oxiracetam crystal formation II |
| CN107021903A (en) * | 2016-01-29 | 2017-08-08 | 重庆润泽医药有限公司 | A kind of levo-oxiracetam crystal formation I preparation method |
| CN106496089B (en) * | 2016-02-05 | 2019-05-21 | 华润双鹤药业股份有限公司 | A method of preparing Oxiracetam |
| CN108659004B (en) * | 2018-07-12 | 2020-11-10 | 福安药业集团重庆博圣制药有限公司 | Preparation method of oxiracetam isomer |
| US11785966B2 (en) | 2019-03-06 | 2023-10-17 | Anipha Technologies Pty Ltd | Use of gamma-quaternary ammonium butyrate compound in preparation of an animal feed additive |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040204476A1 (en) * | 2001-08-10 | 2004-10-14 | Celal Ates | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues |
| CN1869008A (en) * | 2006-06-19 | 2006-11-29 | 张文 | Preparation method of chiral non alpha amino acid derivative of simultaneously protected by hydroxyl group and amino group |
| CN1956953A (en) * | 2004-05-25 | 2007-05-02 | 安国药品株式会社 | Process for the preparation of optically pure 4-hydroxy-2-oxo-1-pyrrolidine acetamide |
| EP1806339A1 (en) * | 2005-12-21 | 2007-07-11 | Ucb, S.A. | Process for the preparation of 2-oxo-1-pyrrolidine derivatives |
| CN101704778A (en) * | 2009-09-30 | 2010-05-12 | 厦门市华兴化工有限公司 | Method for preparing 4-hydroxyl yrrolidone-2-acetamide |
| CN102603597A (en) * | 2011-01-21 | 2012-07-25 | 重庆润泽医疗器械有限公司 | Preparation method of (S)-oxiracetam |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK173685A (en) * | 1984-04-17 | 1985-10-18 | Glaxo Group Ltd | Safety and pouring stopper |
| JP3184758B2 (en) * | 1996-02-02 | 2001-07-09 | 高砂香料工業株式会社 | Method for producing optically active 4-hydroxy-2-pyrrolidone |
-
2013
- 2013-06-19 CN CN201310243165.7A patent/CN104230777B/en active Active
- 2013-06-19 CN CN201610854647.XA patent/CN106631960A/en active Pending
- 2013-06-19 CN CN201610881945.8A patent/CN106478482A/en active Pending
- 2013-06-19 CN CN201610754462.1A patent/CN106349143A/en active Pending
- 2013-06-19 CN CN201610560685.4A patent/CN106146379B/en active Active
- 2013-06-19 CN CN201610882486.5A patent/CN106631963A/en active Pending
- 2013-06-19 CN CN201610854853.0A patent/CN106631961A/en active Pending
- 2013-06-19 CN CN201610560643.0A patent/CN105968024A/en active Pending
- 2013-06-19 CN CN201610750215.4A patent/CN106349142A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040204476A1 (en) * | 2001-08-10 | 2004-10-14 | Celal Ates | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues |
| CN1956953A (en) * | 2004-05-25 | 2007-05-02 | 安国药品株式会社 | Process for the preparation of optically pure 4-hydroxy-2-oxo-1-pyrrolidine acetamide |
| EP1806339A1 (en) * | 2005-12-21 | 2007-07-11 | Ucb, S.A. | Process for the preparation of 2-oxo-1-pyrrolidine derivatives |
| CN1869008A (en) * | 2006-06-19 | 2006-11-29 | 张文 | Preparation method of chiral non alpha amino acid derivative of simultaneously protected by hydroxyl group and amino group |
| CN101704778A (en) * | 2009-09-30 | 2010-05-12 | 厦门市华兴化工有限公司 | Method for preparing 4-hydroxyl yrrolidone-2-acetamide |
| CN102603597A (en) * | 2011-01-21 | 2012-07-25 | 重庆润泽医疗器械有限公司 | Preparation method of (S)-oxiracetam |
Non-Patent Citations (3)
| Title |
|---|
| New enantioselective synthesis of 4-hydroxy-2-oxopyrrolidine-N-acetamide(Oxiracetam) from malic acid;Jesus F. ALMEIDA，等;《Tetrahedron: Asymmetry》;19921231;第3卷(第11期);第1431-1440页 * |
| 促智药物(S)-奥拉西坦的合成;李坤，等;《中国新药杂志》;20111231;第20卷(第19期);第1920-1925页 * |
| 奥拉西坦的合成工艺改进;杨英梅，等;《河北工业科技》;20130531;第30卷(第3期);第212-214页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106349143A (en) | 2017-01-25 |
| CN106631960A (en) | 2017-05-10 |
| CN104230777A (en) | 2014-12-24 |
| CN106631963A (en) | 2017-05-10 |
| CN106146379A (en) | 2016-11-23 |
| CN106631961A (en) | 2017-05-10 |
| CN106349142A (en) | 2017-01-25 |
| CN105968024A (en) | 2016-09-28 |
| CN106146379B (en) | 2018-03-20 |
| CN106478482A (en) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104230777B (en) | A kind of synthetic method of oxiracetam | |
| CN105330582B (en) | (R) preparation method of-Esomeprazole | |
| CN102127005B (en) | Intermediate of alvimopan and synthesis method thereof | |
| CN106349245A (en) | Sitagliptin phosphate impurities, method for preparing same and application of sitagliptin phosphate impurities | |
| CN105330581A (en) | Preparation method for (S)-oxiracetam | |
| CN102964269B (en) | Novel preparation method of iopromide | |
| CN103554031B (en) | Preparation method of azilsartan intermediate | |
| CN102485723A (en) | Semi-synthesis of vinpocetine through one kettle way and preparation of water-soluble vinpocetine salt | |
| CN103601645A (en) | Preparation method of 1-(phenethylamino) propane-2-alcoholic compounds or salts thereof | |
| CN105111103A (en) | Method for preparing cyanophenol and derivative thereof | |
| CN103880756B (en) | The preparation method of a kind of Azilsartan intermediate | |
| CN105315256A (en) | Industrialization-suitable preparation method of high-purity trelagliptin succinate | |
| CN105085510A (en) | Preparation method of (S)-4-oxo-2-(thiazolidine-3-carbonyl) pyrrolidone-1-carboxylic acid tert-butyl ester | |
| CN104557877A (en) | Avanafil intermediate as well as preparation method and application thereof | |
| CN104725292A (en) | Preparation method of (S)(-)-amisulpride | |
| CN104030958A (en) | Synthesis method of (S)-1-(2-chloracetyl) pyrrolidine-2-formonitrile | |
| CN105439936A (en) | Oxiracetam preparation method | |
| CN103739542B (en) | The preparation method of 3- (2- nitriles ethyl) -5- methyl -2,6- dimethyl -4- (3- nitrobenzophenones) -1,4- dichloropyridine-3,5-carboxylic-acid esters | |
| CN110563721A (en) | Preparation method of azasetron hydrochloride | |
| CN104086475A (en) | Preparation method of N-carbobenzoxy-L-prolinamide | |
| CN111333529A (en) | Preparation method of pregabalin | |
| CN104151299B (en) | Compound, crystal-form compound and preparation method thereof | |
| CN109369494B (en) | Preparation method of N-phenylacetyl-L-proline | |
| CN102887851B (en) | Compound 3,5-dimethyl-1H-pyrrole-2,4-diformaldehyde and preparation method thereof | |
| CN107253940A (en) | Application of the asymmetric o conjugate addition reactions in the synthesis of Ao Gelieting intermediates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 400042 Chongqing city Yubei District Qinye Road No. 9 Applicant after: Chongqing Runze Pharmaceutical Co., Ltd. Applicant after: Chengdu Biotop Pharma. Technology Co.,Ltd. Address before: 610065 Sichuan, Chengdu, South Ring Road, No. 1, No. 24 Applicant before: Chengdu Biotop Pharma. Technology Co.,Ltd. Applicant before: Chongqing Runze Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |